Our data provide experimental evidence that combinatorial treatment approaches with TRAIL- and XIAP-targeting molecules such as SMAC mimetics or XIAP-selective agents potentially extend the currently limited therapeutic options of PIK3CA-mutated CRC. The gene discussed is TNFSF10; the disease is colorectal carcinoma.